CELC Celcuity Inc.
Price Chart
Executive Summary
Celcuity announced detailed Phase 3 VIKTORIA-1 results showing its gedatolisib-triplet (gedatolisib + fulvestrant + palbociclib) doubled median progression-free survival to 11.1 months vs 5.6 months for alpelisib + fulvestrant (HR=0.50, p<0.0001) in PIK3CA-mutant HR+/HER2- advanced breast cancer, with a 48.9% objective response rate and lower discontinuation rates (2.6% vs 7.1%). The company also noted its existing NDA for the wild-type cohort is under Priority Review with a PDUFA date of July 17, 2026, and it plans to submit these data as an sNDA.
Actionable Insight
This is a best-case data readout that substantially de-risks the gedatolisib program ahead of the July 17 PDUFA. The combination of superior efficacy (2x PFS) and better tolerability vs the current standard-of-care alpelisib positions gedatolisib for potential label expansion into the larger PIK3CA-mutant population. Monitor for sNDA submission timing and any FDA advisory committee meeting. The stock should re-rate upward on the probability of a broad commercial launch in Q3 2026.
Key Facts
- Gedatolisib-triplet reduced risk of disease progression or death by 50% vs alpelisib + fulvestrant (HR=0.50; 95% CI: 0.37-0.68; p<0.0001)
- Median PFS: 11.1 months (gedatolisib-triplet) vs 5.6 months (alpelisib + fulvestrant)
- Objective response rate: 48.9% (gedatolisib-triplet) vs 26.0% (alpelisib + fulvestrant)
- Treatment discontinuation due to adverse events: 2.6% (gedatolisib-triplet) vs 7.1% (alpelisib + fulvestrant)
- FDA has granted Priority Review for NDA in PIK3CA wild-type ABC with PDUFA goal date of July 17, 2026
- Company plans to submit these data as an sNDA to FDA and to other regulatory authorities
- Company states it is on track for potential FDA approval and commercial launch in Q3 2026
Financial Impact
Transformative for a $6B market cap clinical-stage biotech — gedatolisib now has two positive Phase 3 readouts (WT and MT cohorts) with best-in-class efficacy and safety vs standard-of-care alpelisib, supporting a broad label in HR+/HER2- advanced breast cancer. Peak sales potential is multi-billion dollar if approved in both WT and MT populations.
Risk Factors
- FDA approval is not guaranteed despite Priority Review; a complete response letter would be severely negative
- Commercial launch execution risk for a first-time commercial-stage biotech
- Competition from other PI3K/AKT/mTOR inhibitors in development
- Overall survival data is still immature — a negative OS signal could limit label or uptake
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026761 |
| Document: form8-k.htm | 0001493152-26-026761 |
| Document: 0001493152-26-026761-index-headers.html | 0001493152-26-026761 |
| Document: 0001493152-26-026761-index.html | 0001493152-26-026761 |
| Document: 0001493152-26-026761.txt | 0001493152-26-026761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
1d ago
|
424B5
| — | awaiting T+1 | — | — |
|
Jun 4, 2026
2d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
Jun 3, 2026
3d ago
|
Press Release
| $88.95 $92.47 | ▼ −3.96% | ▼ −3.56% | $88.28 (+0.75%) |
|
Jun 3, 2026
3d ago
|
424B5
| $88.95 $92.47 | ▼ −3.96% | ▼ −3.56% | $88.28 (+0.75%) |
|
Jun 2, 2026
4d ago
|
8-K
| $91.42 $88.95 | ▼ −2.70% | ▼ −2.01% | $88.28 (−3.43%) |
|
May 14, 2026
23d ago
|
Press Release
| $137.68 $132.18 | ▼ −3.99% | ▼ −3.93% | $88.28 (−35.88%) |
|
May 7, 2026
4w ago
|
Press Release
| $130.71 $131.06 | ▲ +0.27% | ▼ −0.56% | $88.28 (−32.46%) |
|
May 4, 2026
4w ago
|
144
| $144.98 $141.69 | ▼ −2.27% | ▼ −3.06% | $88.28 (−39.11%) |
|
May 1, 2026
5w ago
|
Press Release
| $144.98 $141.69 | ▼ −2.27% | ▼ −3.06% | $88.28 (−39.11%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $114.81 $106.02 | ▼ −7.66% | ▼ −5.98% | $88.28 (−23.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access